Osborne Partners Capital Management’s GSK GSK Stock Holding History

Osborne Partners Capital Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-20,433	Closed	-$940K	–	205
2020 Q4	$940K	Buy	+20,433	New	+$939K	0.11%	119
2019 Q1	–	Sell	-20,537	Closed	-$981K	–	170
2018 Q4	$981K	Hold	20,537	–	–	0.15%	110
2018 Q3	$1.03M	Sell	20,537 -209	-1%	-$10.6K	0.13%	110
2018 Q2	$1.04M	Buy	20,746 +209	+1%	+$10.5K	0.14%	107
2018 Q1	$1M	Sell	20,537 -56	-0.3%	-$2.61K	0.14%	109
2017 Q4	$913K	Buy	20,593 +56	+0.3%	+$2.59K	0.12%	115
2017 Q3	$1.04M	Hold	20,537	–	–	0.14%	116
2017 Q2	$1.11M	Hold	20,537	–	–	0.16%	106
2017 Q1	$1.08M	Sell	20,537 -1,085	-5%	-$55K	0.15%	109
2016 Q4	$1.04M	Sell	21,622 -75	-0.3%	-$3.71K	0.15%	110
2016 Q3	$1.17M	Sell	21,697 -320	-1%	-$17.5K	0.18%	103
2016 Q2	$1.19M	Hold	22,017	–	–	0.18%	105
2016 Q1	$1.12M	Hold	22,017	–	–	0.16%	107
2015 Q4	$1.11M	Buy	22,017 +320	+1%	+$16.3K	0.16%	108
2015 Q3	$1.04M	Sell	21,697 -21,320	-50%	-$1.11M	0.15%	110
2015 Q2	$2.24M	Sell	43,017 -313	-0.7%	-$17.6K	0.3%	83
2015 Q1	$2.5M	Sell	43,330 -109	-0.3%	-$6.25K	0.33%	79
2014 Q4	$2.32M	Sell	43,439 -230	-0.5%	-$12.9K	0.28%	82
2014 Q3	$2.51M	Buy	43,669 +203	+0.5%	+$12.4K	0.32%	74
2014 Q2	$2.91M	Sell	43,466 -348	-0.8%	-$23.6K	0.37%	71
2014 Q1	$2.93M	Buy	43,814 +388	+0.9%	+$26.2K	0.38%	68
2013 Q4	$2.9M	Sell	43,426 -478	-1%	-$31K	0.38%	68
2013 Q3	$2.75M	Hold	43,904	–	–	0.38%	67
2013 Q2	$2.74M	Buy	+43,904	New	+$2.79M	0.39%	67

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BCIM

Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return

Osborne Partners Capital Management's GSK Position: Q1 2021 in Review

Osborne Partners Capital Management sold out of GSK (GSK) in Q1 2021, closing a stake of 20,433 shares — an estimated $940K sold.

Osborne Partners Capital Management first reported a position in GSK in Q2 2013 and held it in 24 quarters. The position peaked at $2.93M in Q1 2014. 774 funds tracked by Wall St. Rank hold GSK as of Q1 2021.

Osborne Partners Capital Management reported no remaining GSK position as of Q1 2021 after selling out during the quarter.
Osborne Partners Capital Management sold 20,433 GSK shares in Q1 2021, an estimated $940K.
Osborne Partners Capital Management first reported a position in GSK in Q2 2013 and held it in 24 quarters.
Osborne Partners Capital Management's GSK position peaked at $2.93M in Q1 2014.
774 funds tracked by Wall St. Rank held GSK as of Q1 2021.

Based on Osborne Partners Capital Management's 13F filing for Q1 2021, filed 27 Apr 2021.